Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 9
2011 7
2012 20
2013 28
2014 36
2015 45
2016 34
2017 35
2018 34
2019 33
2020 14
2021 19
2022 15
2023 14
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

295 results

Results by year

Filters applied: . Clear all
Page 1
Nanogel enhances the efficacy of MLN8237 in treating hepatocellular carcinoma.
Gao W, Shen R. Gao W, et al. J Biomater Appl. 2023 Oct;38(4):527-537. doi: 10.1177/08853282231202326. Epub 2023 Sep 11. J Biomater Appl. 2023. PMID: 37695622
Therefore, this study aims to investigate the increase in the effect of nanogels on MLN8237 in inhibiting HCC. Doxorubicin or MLN8237 was used as an anti-tumor drug models which were packaged by organic solvent volatilization method to obtain the doxorubicin-loaded …
Therefore, this study aims to investigate the increase in the effect of nanogels on MLN8237 in inhibiting HCC. Doxorubicin or MLN8 …
MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.
Alrifai D, Pettengell R. Alrifai D, et al. Expert Opin Investig Drugs. 2014 Dec;23(12):1731-6. doi: 10.1517/13543784.2014.972501. Epub 2014 Oct 17. Expert Opin Investig Drugs. 2014. PMID: 25323772 Review.
AREAS COVERED: The authors review the evidence for the orally administered aurora A kinase inhibitor MLN8237 ( alisertib ) in T-cell lymphoma. No significant association between clinical response and AAK expression has been observed but inhibition of this enzyme in a Phase …
AREAS COVERED: The authors review the evidence for the orally administered aurora A kinase inhibitor MLN8237 ( alisertib ) in T-cell …
MLN8237 treatment in an orthoxenograft murine model for malignant peripheral nerve sheath tumors.
Payne R, Mrowczynski OD, Slagle-Webb B, Bourcier A, Mau C, Aregawi D, Madhankumar AB, Lee SY, Harbaugh K, Connor J, Rizk EB. Payne R, et al. J Neurosurg. 2018 Feb 1:1-11. doi: 10.3171/2017.8.JNS17765. Online ahead of print. J Neurosurg. 2018. PMID: 29473773
The MLN8237 group also showed decreased tumor size compared with the doxorubicin/ifosfamide group at the conclusion of the study (p = 0.036). ...A hazard ratio comparing the 2 treatment groups showed a decreased hazard rate in the MLN8237 group compared with the dox …
The MLN8237 group also showed decreased tumor size compared with the doxorubicin/ifosfamide group at the conclusion of the study (p = …
Aurora kinase a inhibitor MLN8237 suppresses pancreatic cancer growth.
Zhang Y, Ma Y, Wang Y, Mukhopadhyay D, Bi Y, Ji B. Zhang Y, et al. Pancreatology. 2022 Jun;22(5):619-625. doi: 10.1016/j.pan.2022.03.019. Epub 2022 Apr 13. Pancreatology. 2022. PMID: 35550115 Free PMC article.
Here we report that Aurora kinase-A expression is elevated in both human and mouse PDAC samples. MLN8237, an inhibitor of Aurora kinase-A, efficiently reduced the proliferation and motility of PDAC cells in vitro as well as tumor growth in orthotropic xenograft model and g …
Here we report that Aurora kinase-A expression is elevated in both human and mouse PDAC samples. MLN8237, an inhibitor of Aurora kina …
The Cancer SENESCopedia: A delineation of cancer cell senescence.
Jochems F, Thijssen B, De Conti G, Jansen R, Pogacar Z, Groot K, Wang L, Schepers A, Wang C, Jin H, Beijersbergen RL, Leite de Oliveira R, Wessels LFA, Bernards R. Jochems F, et al. Cell Rep. 2021 Jul 27;36(4):109441. doi: 10.1016/j.celrep.2021.109441. Cell Rep. 2021. PMID: 34320349 Free PMC article.
Critical risk-benefit assessment of the novel anti-cancer aurora a kinase inhibitor alisertib (MLN8237): A comprehensive review of the clinical data.
Tayyar Y, Jubair L, Fallaha S, McMillan NAJ. Tayyar Y, et al. Crit Rev Oncol Hematol. 2017 Nov;119:59-65. doi: 10.1016/j.critrevonc.2017.09.006. Epub 2017 Sep 18. Crit Rev Oncol Hematol. 2017. PMID: 29065986 Review.
This resulted in the exploration of inhibitors of Aurora A kinase as a potential anti-cancer treatment. Alisertib (MLN8237) has proven to be a potent Aurora A kinase inhibitor that had the highest safety profile among its therapeutic family. ...
This resulted in the exploration of inhibitors of Aurora A kinase as a potential anti-cancer treatment. Alisertib (MLN8237) has prove …
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T, Cheung C, Yuen KS, Gao D, Chen Y, Eilers M, Mosquera JM, Robinson BD, Elemento O, Rubin MA, Demichelis F, Rickman DS. Dardenne E, et al. Cancer Cell. 2016 Oct 10;30(4):563-577. doi: 10.1016/j.ccell.2016.09.005. Cancer Cell. 2016. PMID: 27728805 Free PMC article.
Sensitisation of Cancer Cells to MLN8237, an Aurora-A Inhibitor, by YAP/TAZ Inactivation.
Oku Y, Nishiya N, Sugiyama S, Sato H, Uehara Y. Oku Y, et al. Anticancer Res. 2018 Jun;38(6):3471-3476. doi: 10.21873/anticanres.12617. Anticancer Res. 2018. PMID: 29848699
RESULTS: Depletion of either YAP or TAZ sensitised these cell lines to MLN8237, resulting in apoptosis and reduction in aurora-A. MLN8237 reduced YAP/TAZ expression. A combination of MLN8237 with fluvastatin effectively reduced the cell viability of OVCAR-8 a …
RESULTS: Depletion of either YAP or TAZ sensitised these cell lines to MLN8237, resulting in apoptosis and reduction in aurora-A. …
Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.
Dickson MA, Mahoney MR, Tap WD, D'Angelo SP, Keohan ML, Van Tine BA, Agulnik M, Horvath LE, Nair JS, Schwartz GK. Dickson MA, et al. Ann Oncol. 2016 Oct;27(10):1855-60. doi: 10.1093/annonc/mdw281. Epub 2016 Aug 8. Ann Oncol. 2016. PMID: 27502708 Free PMC article. Clinical Trial.
The inhibition of AURKA by shRNA or by a specific AURKA inhibitor blocks in vitro proliferation of multiple sarcoma subtypes. MLN8237 (alisertib) is a novel oral adenosine triphosphate-competitive AURKA inhibitor. ...
The inhibition of AURKA by shRNA or by a specific AURKA inhibitor blocks in vitro proliferation of multiple sarcoma subtypes. MLN8237 …
Differentiation therapy for murine myelofibrosis model with MLN8237 loaded low-density lipoproteins.
He B, Wang C, Wang F, Tian L, Wang H, Fu C, Liu J, Xi C, Zhu C, Yang Q. He B, et al. J Control Release. 2023 Apr;356:554-566. doi: 10.1016/j.jconrel.2023.03.024. Epub 2023 Mar 17. J Control Release. 2023. PMID: 36924895
In particular, the reconstituted low-density lipoprotein (rLDL) nanocarrier and the loaded MLN8237 can actively target malignant hematopoietic stem/progenitor cells (HSPCs) via LDL receptors and intracellular AURKA, respectively. ...Surprisingly, even at a 1500-fold lower …
In particular, the reconstituted low-density lipoprotein (rLDL) nanocarrier and the loaded MLN8237 can actively target malignant hema …
295 results